Grifols delivers first manufactured batches of its coronavirus treatment for clinical trials
CLAYTON – Grifols, a global leader in the development of therapies with plasma-derived proteins, today announced it has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials. Since April, Grifols began […]